Straits Times Index
3,407.92 +40.02 (+1.19%) Nikkei
40,580.76 +506.07 (+1.26%) Hang Seng
17,978.57 +209.43 (+1.18%) FTSE 100
8,156.40 +35.20 (+0.43%) Bitcoin USD
60,652.61 -1,989.03 (-3.18%) CMC Crypto 200
1,307.61 -27.31 (-2.05%)
Korro Bio, Inc. (KRRO)
After hours:
| Previous close | 33.85 |
| Open | 33.63 |
| Bid | 32.32 x 100 |
| Ask | 34.27 x 100 |
| Day's range | 32.92 - 35.78 |
| 52-week range | 9.15 - 97.91 |
| Volume | |
| Avg. volume | 68,746 |
| Market cap | 307.029M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -10.11 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 126.25 |
GlobeNewswireKorro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes
CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that it has been added to the Russell 2000®, Russell 3000®, and the Russell Microcap® Indexes as part of the annual reconstitution, effective at the open of US equity markets today, Monday, July 1. The annual Russell US Indexes reconstitution c
- GlobeNewswire
Korro to Participate in Upcoming June Investor and Scientific Conferences
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences: Jefferies Global Healthcare Conference Chief Executive Officer and President, Ram Aiyar, Ph.D., will present on Thursday, June 6, 2024, at 2:00 p.m. ET. Chief Financial Officer, Vineet Agarwal, will also be participating at the conference. 2024 Alpha-1 Foundation National ConferenceChie
- GlobeNewswire
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) mouse modelKRRO-110 showed 35µM of M-AAT one week post the first dose, with 0µM of M-AAT at baseline, increasing to 45µM of M-AAT at week 13 CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing
